Zacks Investment Research
11 Jun 2026, 15:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Top 2 movers · tap to explore
What the story claims
3 claims · each scored for market impact
Harrow (HROW) relaunched Verkazia, an FDA-approved nonsteroidal eye drop for vernal keratoconjunctivitis, in the United States. — The relaunch aims to solve supply chain issues and address an unmet medical need, creating a new revenue stream for a priority product.
+0.40Harrow currently holds a Zacks Rank #4 (Sell). — A 'Sell' rating from a quantitative research provider suggests underlying fundamental weakness despite the recent product news.
-0.30Harrow shares have declined 26.8% year-to-date, significantly underperforming the biotech industry's 9.9% decline. — Strong negative momentum and relative underperformance indicate poor investor confidence in the stock's current trajectory.
-0.10Which stocks this story touches
Continue reading
6 related stories
Shares rose 7.3% following the relaunch of Verkazia, although the stock has lost 26.8% year-to-date and holds a 'Sell' rank.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
Proactive Investors
7h ago
